



20th October 2021

Licence agreement with TRx Biosciences Limited

Oxilio signed an exclusive global licensing agreement with TRx Biosciences Ltd, a privately held pharmaceutical development company, for its patent rights and know-how connected with the TRx platform technology. Oxilio will use this technology for the development and commercialisation of an optimised compound formulation in the field of cancer treatment.

The TRx technology enables targeted oral drug delivery to specific organs, cells and tissues in cancer using a clinically and commercially proven approach.